2019
Liraglutide in Children and Adolescents with Type 2 Diabetes
Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T. Liraglutide in Children and Adolescents with Type 2 Diabetes. New England Journal Of Medicine 2019, 381: 637-646. PMID: 31034184, DOI: 10.1056/nejmoa1903822.Peer-Reviewed Original ResearchConceptsGlycated hemoglobin levelsType 2 diabetesGastrointestinal adverse eventsAdverse eventsPlasma glucose levelsHemoglobin levelsEnd pointGlycemic controlGlucose levelsMean glycated hemoglobin levelOpen-label extension periodPrimary efficacy end pointDose of liraglutideDouble-blind periodEfficacy end pointPrimary end pointSecondary end pointsBody mass indexNumber of patientsYears of ageMetformin monotherapySubcutaneous liraglutidePlacebo groupLiraglutide groupInclusion criteria
2013
Factors Associated With Microalbuminuria in 7,549 Children and Adolescents With Type 1 Diabetes in the T1D Exchange Clinic Registry
Daniels M, DuBose SN, Maahs DM, Beck RW, Fox LA, Gubitosi-Klug R, Laffel LM, Miller KM, Speer H, Tamborlane WV, Tansey MJ, . Factors Associated With Microalbuminuria in 7,549 Children and Adolescents With Type 1 Diabetes in the T1D Exchange Clinic Registry. Diabetes Care 2013, 36: 2639-2645. PMID: 23610082, PMCID: PMC3747908, DOI: 10.2337/dc12-2192.Peer-Reviewed Original ResearchConceptsT1D Exchange Clinic RegistryAngiotensin receptor blockersType 1 diabetesMA diagnosisDiabetes durationBlood pressureACE inhibitorsClinic registryACEI/ARB treatmentHigher diastolic blood pressureOlder ageRisk of nephropathyLonger diabetes durationDiastolic blood pressureYears of ageBP controlGood glycemicARB treatmentReceptor blockersCreatinine ratioNonmodifiable factorsUrinary albuminHemoglobin levelsFemale sexCurrent treatment
2012
A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes
Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan D, Tollefsen S, Wilfley D, Kaufman F. A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes. New England Journal Of Medicine 2012, 366: 2247-2256. PMID: 22540912, PMCID: PMC3478667, DOI: 10.1056/nejmoa1109333.Peer-Reviewed Original ResearchConceptsType 2 diabetesDurable glycemic controlGlycated hemoglobin levelsGlycemic controlLifestyle interventionPrimary outcomeHemoglobin levelsRecent-onset type 2 diabetesIntensive lifestyle interventionSerious adverse eventsLifestyle intervention programAddition of rosiglitazoneNon-Hispanic black participantsHalf of childrenYears of ageAdverse eventsPatients 10Prespecified analysisMetabolic decompensationRate of failureTreatment regimensClinical trialsMetforminType 2RosiglitazoneThe Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence
Ruedy KJ, Tamborlane WV, for the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence. Journal Of Cardiovascular Translational Research 2012, 5: 380-387. PMID: 22538483, DOI: 10.1007/s12265-012-9364-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBiomarkersBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1Equipment DesignEvidence-Based MedicineGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsMulticenter Studies as TopicPatient SatisfactionPredictive Value of TestsRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsContinuous glucose monitorRandomized trialsT1D managementMulticenter Randomized TrialType 1 diabetesStandard glucose monitoringPrimary studiesComplications TrialSevere hypoglycemiaHemoglobin levelsDiabetes controlBiochemical hypoglycemiaCGM usePatientsGlucose monitoringAccumulated evidenceSecondary studiesReduced exposureTrialsA1CHypoglycemiaGlucose monitorSubjectsDCCTDiabetes
2010
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal Of Medicine 2010, 363: 311-320. PMID: 20587585, DOI: 10.1056/nejmoa1002853.Peer-Reviewed Original ResearchConceptsInjection therapy groupPump-therapy groupSensor-augmented pump therapyGlycated hemoglobin levelsHemoglobin levelsType 1 diabetesPump therapyBaseline glycated hemoglobin levelMultiple daily insulin injectionsType 1 diabetes mellitusGlycated haemoglobin targetPrimary end pointProportion of patientsDaily insulin injectionsSignificant weight gainRecombinant insulin analogueHemoglobin targetsInjection therapyDiabetes mellitusSevere hypoglycemiaInsulin injectionsClinical teamInsulin analoguesEnd pointTherapy
2008
Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes
Tamborlane W, Beck R, Bode B, Buckingham B, Chase H, Clemons R, Fiallo-Scharer R, Fox L, Gilliam L, Hirsch I, Huang E, Kollman C, Kowalski A, Laffel L, Lawrence J, Lee J, Mauras N, O'Grady M, Ruedy K, Tansey M, Tsalikian E, Weinzimer S, Wilson D, Wolpert H, Wysocki T, Xing D. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. New England Journal Of Medicine 2008, 359: 1464-1476. PMID: 18779236, DOI: 10.1056/nejmoa0805017.Peer-Reviewed Original ResearchConceptsYears of ageContinuous glucose monitoringContinuous monitoring groupPatients 25 yearsGlycated hemoglobin levelsType 1 diabetesHemoglobin levelsGlucose monitoringStudy groupControl groupType 1 diabetes mellitusMulticenter clinical trialBetween-group differencesHemoglobin outcomesYounger patientsDiabetes mellitusGlycemic controlIntensive therapyPrimary outcomeSevere hypoglycemiaClinical trialsIntensive treatmentAge groupsBlood glucose metersType 1
2006
Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes
Tamborlane WV, Sikes KA, Steffen AT, Weinzimer SA. Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes. Diabetes Research And Clinical Practice 2006, 74: s112-s115. PMID: 17182301, DOI: 10.1016/s0168-8227(06)70011-0.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionSubcutaneous insulin infusionType 1 diabetesInsulin infusionEfficacy of CSIIExcessive weight gainInsulin pump therapyNew insulin analoguesQuality of lifePediatric patientsSevere hypoglycemiaHemoglobin levelsPump therapyTreatment optionsClinical studiesInsulin analoguesWeight gainDiabetesInfusionChildrenRecent studiesSafetyHypoglycemiaPatientsTherapyThe renaissance of insulin pump treatment in childhood type 1 diabetes
Tamborlane WV, Swan K, Sikes KA, Steffen AT, Weinzimer SA. The renaissance of insulin pump treatment in childhood type 1 diabetes. Reviews In Endocrine And Metabolic Disorders 2006, 7: 205-213. PMID: 17160722, DOI: 10.1007/s11154-006-9018-9.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionQuality of lifePump therapyEfficacy of CSIINormal blood sugar levelsType 1 diabetes mellitusChildhood type 1 diabetesRisk of hypoglycemiaInsulin pump therapyBlood sugar levelsSubcutaneous insulin infusionType 1 diabetesNew insulin analoguesTreatment of childrenMacrovascular complicationsDiabetes mellitusPediatric patientsSevere hypoglycemiaHemoglobin levelsPatient selectionTreatment optionsInsulin infusionClinical studiesAge of childrenInsulin analogues
2005
Insulin Pump Treatment of Childhood Type 1 Diabetes
Weinzimer SA, Sikes KA, Steffen AT, Tamborlane WV. Insulin Pump Treatment of Childhood Type 1 Diabetes. Pediatric Clinics Of North America 2005, 52: 1677-1688. PMID: 16301088, DOI: 10.1016/j.pcl.2005.07.004.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionQuality of lifeLong-term microvascular complicationsEfficacy of CSIINormal blood sugar levelsType 1 diabetes mellitusInsulin pump treatmentChildhood Type 1Risk of hypoglycemiaBlood sugar levelsSubcutaneous insulin infusionNew insulin analoguesTreatment of childrenMicrovascular complicationsDiabetes mellitusPump treatmentSevere hypoglycemiaHemoglobin levelsTreatment optionsInsulin infusionClinical studiesAge of childrenInsulin analoguesType 1Weight gainDiabetes in overweight pediatric patients
Tamborlane WV. Diabetes in overweight pediatric patients. Clinical Cornerstone 2005, 7: s25-s29. PMID: 16545735, DOI: 10.1016/s1098-3597(05)80086-9.Peer-Reviewed Original ResearchConceptsDiabetes mellitusNew-onset type 2 diabetes mellitusType 2 diabetes mellitusChildhood diabetes mellitusOverweight pediatric patientsNew diabetes casesMore effective treatmentsPediatric patientsHemoglobin levelsInadequate therapyDiabetes casesDiabetic complicationsPatient satisfactionUrine testingFamily historyEffective treatmentDM treatmentBetter outcomesMetabolic controlInsulin analoguesType 2Ethnic minority groupsHigh rateDiseasePromising new avenue
2004
Rediscovery of insulin pump treatment of childhood type 1 diabetes.
Weinzimer SA, Doyle EA, Steffen AT, Sikes KA, Tamborlane WV. Rediscovery of insulin pump treatment of childhood type 1 diabetes. Minerva Medica 2004, 95: 85-92. PMID: 15272243.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionInsulin pump therapyQuality of lifeSevere hypoglycemiaPump therapyLong-term microvascular complicationsEfficacy of CSIIType 1 diabetes mellitusWeight gainChildhood type 1 diabetesExcessive weight gainBasal infusion rateSubcutaneous insulin infusionType 1 diabetesNew insulin analoguesTreatment of childrenContinuous glucose monitoringMicrovascular complicationsDiabetes mellitusPediatric patientsHemoglobin levelsNocturnal hypoglycemiaTreatment optionsNormal glycemiaInsulin infusion
1982
Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy.
Tamborlane WV, Puklin JE, Bergman M, Verdonk C, Rudolf MC, Felig P, Genel M, Sherwin R. Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy. Diabetes Care 1982, 5 Suppl 1: 58-64. PMID: 7188047.Peer-Reviewed Original ResearchConceptsPump treatmentProliferative retinopathyMetabolic controlInsulin pumpType I diabetic patientsFirst monthInsulin pump treatmentRetinal fluorescein leakageDiabetic microvascular complicationsTotal daily doseNormal glucose metabolismLong-term improvementBackground retinopathyMicrovascular complicationsCreatinine clearanceDiabetic nephropathyRenal functionSerum creatinineDaily doseDiabetic patientsDiabetic microangiopathyHemoglobin levelsPump therapyPlasma glucoseClinical endpoints